# Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

> **NCT01471717** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** INX-08189 50 mg QD X 5 days
- **DRUG:** INX-08189 / Victrelis 800 mg TID X three days
- **DRUG:** Victrelis 800 mg TID x 3 days
- **DRUG:** Victrelis 800 mg TID with INX-08189 50 mg QD
- **DRUG:** Placebo with Victrelis 800 mg
- **DRUG:** Cohort 2: Victrelis 800 mg with Placebo

## Key facts

- **NCT ID:** NCT01471717
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471717, "Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01471717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*